Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 1/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4418068 | 0.81 | LMNA (0.48) | LMNASMN1; SMN2RAB9AMGLLHCRTR2 | |
| SCHEMBL4418064 | 0.81 | LMNA (0.48) | LMNASMN1; SMN2RAB9AMGLLHCRTR2 | |
| SCHEMBL4422567 | 0.76 | LMNA (0.79) | LMNASMN1; SMN2MGLLHCRTR2MEN1 | |
| SCHEMBL8343101 | 0.73 | MEN1 (0.48) | LMNASMN1; SMN2RAB9AMEN1KMT2A | |
| SCHEMBL8340571 | 0.70 | MEN1 (0.45) | LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL8346666 | 0.70 | SMN1; SMN2 (0.50) | LMNASMN1; SMN2POLBMGLLMEN1 | |
| SCHEMBL4429170 | 0.69 | LMNA (0.67) | LMNASMN1; SMN2MGLLMEN1KMT2A | |
| SCHEMBL4429146 | 0.68 | LMNA (0.65) | LMNASMN1; SMN2POLBRAB9AMGLL | |
| SCHEMBL6195822 | 0.65 | LMNA (1.00) | LMNASMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL12868271 | 0.63 | LMNA (0.59) | LMNASMN1; SMN2HCRTR2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553967-B2 | 1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections | WYETH (US) | 2009-06-30 | — | — | US | claimed |
| WO-2005090309-A1 | 1,2-DIHYDROQUINOLINE DERIVATIVES AND METHOD FOR USING THE SAME TO TREAT HIV INFECTION | WYETH (US) | 2005-09-29 | — | — | WO | claimed |
| US-20050203129-A1 | 1, 2-Dihydroquinoline derivatives and method for using the same to treat HIV infections | WYETH | 2005-09-15 | — | — | US | claimed |
| US-7553967-B2 | 1,2-Dihydroquinoline derivatives and method for using the same to treat HIV infections | WYETH (US) | 2009-06-30 | — | — | US | disclosed |
| WO-2005090309-A1 | 1,2-DIHYDROQUINOLINE DERIVATIVES AND METHOD FOR USING THE SAME TO TREAT HIV INFECTION | WYETH (US) | 2005-09-29 | — | — | WO | disclosed |
| US-20050203129-A1 | 1, 2-Dihydroquinoline derivatives and method for using the same to treat HIV infections | WYETH | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203129-A1 | 1, 2-Dihydroquinoline derivatives and method for using the same to treat HIV infections | CBR3, CBR1, NR1H3 | LMNA 4140/4885SMN1; SMN2 4136/4885POLB 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.